Align Technology, Inc. (NASDAQ:ALGN) Director Greg J. Santora sold 7,700 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $238.95, for a total value of $1,839,915.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The company had revenue of $385.30 million during the quarter, compared to the consensus estimate of $359.80 million. During the same period last year, the business posted $0.63 earnings per share. Align Technology’s revenue was up 38.3% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: This piece was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://theolympiareport.com/2017/11/01/greg-j-santora-sells-7700-shares-of-align-technology-inc-algn-stock.html.

A number of large investors have recently added to or reduced their stakes in ALGN. Schroder Investment Management Group purchased a new stake in Align Technology in the second quarter worth $104,000. CENTRAL TRUST Co increased its position in Align Technology by 128.5% in the second quarter. CENTRAL TRUST Co now owns 697 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 392 shares during the last quarter. Whittier Trust Co. purchased a new stake in Align Technology in the third quarter worth $107,000. Bronfman E.L. Rothschild L.P. increased its position in Align Technology by 13.0% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 912 shares of the medical equipment provider’s stock worth $137,000 after buying an additional 105 shares during the last quarter. Finally, BlueMountain Capital Management LLC purchased a new stake in Align Technology in the second quarter worth $148,000. 80.96% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on ALGN shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $176.00 price target on shares of Align Technology in a research report on Friday, July 28th. Robert W. Baird reaffirmed a “buy” rating and set a $245.00 price target on shares of Align Technology in a research report on Friday, October 27th. Leerink Swann reaffirmed an “outperform” rating and set a $250.00 price target on shares of Align Technology in a research report on Friday, October 27th. Morgan Stanley reaffirmed an “overweight” rating and set a $182.00 price target (up previously from $175.00) on shares of Align Technology in a research report on Monday, July 17th. Finally, Stifel Nicolaus boosted their price target on Align Technology from $205.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Eleven equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $214.45.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Insider Buying and Selling by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.